Skip to main content

Table 2 Pathogens most commonly accounting for IET exposure

From: The risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvHABP), ventilated (vHABP) hospital-acquired and ventilator-associated (VABP) bacterial pneumonia in the US, 2012–2019

 

nvHABP

vHABP

VABP

N

%

N

%

N

%

Pseudomonas aeruginosa

103

24.18

45

17.37

117

18.51

Escherichia coli

51

11.97

38

14.67

35

5.54

MSSA

50

11.74

33

12.74

78

12.34

MRSA

49

11.50

23

8.88

40

6.33

Klebsiella pneumoniae

47

11.03

21

8.11

57

9.02

Enterobacter cloacae

21

4.93

20

7.72

59

9.34

Stenotrophomonas maltophilia

16

3.76

22

8.49

64

10.13

Serratia marcescens

15

3.52

11

4.25

42

6.65

Proteus mirabilis

12

2.82

1

0.39

7

1.11

Acinetobacter baumannii

12

2.82

17

6.56

43

6.80

Other

50

11.74

28

10.81

90

14.24

  1. *"Other” category consists of the organisms listed in Additional file 2: Table S2
  2. IET = inappropriate empiric treatment; nvHABP = non-ventilated hospital-acquired bacterial pneumonia; vHABP = ventilated hospital-acquired bacterial pneumonia; VABP = ventilated hospital-acquired bacterial pneumonia; MSSA = methicillin-susceptible S. aureus; MRSA = methicillin-resistant S. aureus
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us